Literature DB >> 22401488

Risk factors for antidepressant-related switch to mania.

Marc Valentí1, Isabella Pacchiarotti, C Mar Bonnín, Adriane R Rosa, Dina Popovic, Alessandra M A Nivoli, José Manuel Goikolea, Andrea Murru, Juan Undurraga, Francesc Colom, Eduard Vieta.   

Abstract

OBJECTIVE: Treatment of bipolar depression with antidepressants is strongly debated on the basis of the methodologically poor and insufficient data supporting their use and the widely held belief that antidepressants can induce new episodes of abnormal mood elevation or accelerate the rate of cycling. The present study aimed at identifying clinical risk factors for switch into hypomania, mania, or mixed states, within 8 weeks after introduction of an antidepressant or after increasing its dosage, in a prospective, longitudinal design.
METHOD: 221 consecutive DSM-IV-TR depressed bipolar I and II disorder patients were treated with antidepressants, which were added to previously prescribed mood stabilizers and/or atypical antipsychotics. No patient was on antidepressant monotherapy. The patients were enrolled from October 2005 through January 2010. The primary outcome was the assessment of switch to mania or hypomania within 8 weeks after the introduction or dose increase of an antidepressant. Both groups were compared with analysis of variance and χ² procedures.
RESULTS: Treatment-emergent affective switch was detected in 54 patients (24.4%) (switch group) while 167 patients (75.6%) (nonswitch group) did not experience a treatment-related switch. The main clinical differences significantly associated with the occurrence of an antidepressant-related switch, after performing logistic regression analysis, were higher rate of previous switches (P < .001) in the switch versus the nonswitch group, lower rate of responses to antidepressants (P < .001) in the switch versus the nonswitch group, and earlier age at onset (P = .026) in the switch versus the nonswitch group. DISCUSSION: Bipolar patients with an earlier age at onset and an illness course characterized by lower rate of response to antidepressants and higher rate of switches into mania or hypomania were found to be the ones with higher switch risk. Nevertheless, a greater number of previous antidepressant exposures was not associated with the occurrence of an antidepressant-associated switch. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01503489. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22401488     DOI: 10.4088/JCP.11m07166

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

Review 1.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 2.  Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives.

Authors:  Jorge Renner Cardoso de Almeida; Mary Louise Phillips
Journal:  Biol Psychiatry       Date:  2012-07-10       Impact factor: 13.382

3.  Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with comorbid migraine.

Authors:  Erika F H Saunders; Racha Nazir; Masoud Kamali; Kelly A Ryan; Simon Evans; Scott Langenecker; Alan J Gelenberg; Melvin G McInnis
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

Review 4.  An update on antidepressant use in bipolar depression.

Authors:  Michelle M Sidor; Glenda M MacQueen
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

Review 5.  Elevated reward-related neural activation as a unique biological marker of bipolar disorder: assessment and treatment implications.

Authors:  Robin Nusslock; Christina B Young; Katherine S F Damme
Journal:  Behav Res Ther       Date:  2014-09-01

Review 6.  Bipolar disorder diagnosis: challenges and future directions.

Authors:  Mary L Phillips; David J Kupfer
Journal:  Lancet       Date:  2013-05-11       Impact factor: 79.321

7.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

Authors:  Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

8.  Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Mostafa Amr; Ahmed El-Mogy; Tarek Shams; Karen Vieira; Shaheen E Lakhan
Journal:  Nutr J       Date:  2013-03-09       Impact factor: 3.271

9.  Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME).

Authors:  Oğuz Karamustafalıoğlu; Andreas Reif; Murad Atmaca; Domingo Gonzalez; Miriam Moreno-Manzanaro; Miguel Angel Gonzalez; Esteban Medina; Antonello Bellomo
Journal:  BMC Psychiatry       Date:  2014-08-31       Impact factor: 3.630

Review 10.  Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines.

Authors:  Dian-Jeng Li; Ping-Tao Tseng; Yen-Wen Chen; Ching-Kuan Wu; Pao-Yen Lin
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.